SOPHiA GENETICS (NASDAQ:SOPH) Insider Sells 5,000 Shares

Key Points

• Insider selling: Philippe Menu sold 5,000 SOPHiA GENETICS shares at $8.68 each for $43,400 under a pre-arranged Rule 10b5-1 plan, reducing his holdings by 2.29% to 213,387 shares.
• Stock and financial performance: SOPH recently traded at $8.53, near its 12-month high of $8.85. Its latest quarterly loss of $0.26 per share missed estimates, although revenue of $23.31 million exceeded expectations.
• Analyst and institutional view: Institutional investors own 31.59% of the company, while analyst opinions remain mixed; the stock has an overall “Hold” rating and a consensus price target of $10.00.

SOPHiA GENETICS SA (NASDAQ:SOPH - Get Free Report) insider Philippe Menu sold 5,000 shares of the company's stock in a transaction dated Tuesday, August 25th. The shares were sold at an average price of $8.68, for a total transaction of $43,400.00. Following the sale, the insider directly owned 213,387 shares of the company's stock, valued at approximately $1,852,199.16. This represents a 2.29% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Philippe Menu also recently made the following trade(s):

• On Wednesday, August 12th, Philippe Menu sold 5,000 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $7.52, for a total transaction of $37,600.00.
• On Monday, July 27th, Philippe Menu sold 5,000 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $5.66, for a total value of $28,300.00.
• On Monday, July 13th, Philippe Menu sold 5,000 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $5.70, for a total transaction of $28,500.00.
• On Monday, July 6th, Philippe Menu sold 7,393 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $5.16, for a total value of $38,147.88.
• On Thursday, June 25th, Philippe Menu sold 5,000 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $5.50, for a total value of $27,500.00.

SOPHiA GENETICS Stock Down 1.4%

NASDAQ:SOPH traded down $0.12 during mid-day trading on Wednesday, hitting $8.53. The stock had a trading volume of 232,020 shares, compared to its average volume of 241,759. SOPHiA GENETICS SA has a twelve month low of $3.10 and a twelve month high of $8.85. The stock has a 50-day simple moving average of $6.33 and a two-hundred day simple moving average of $5.37. The company has a current ratio of 2.69, a quick ratio of 2.55 and a debt-to-equity ratio of 0.58. The company has a market capitalization of $715.58 million, a PE ratio of -7.42 and a beta of 0.96.

SOPHiA GENETICS (NASDAQ:SOPH - Get Free Report) last released its quarterly earnings data on Wednesday, August 5th. The company reported ($0.26) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.21) by ($0.05). The firm had revenue of $23.31 million for the quarter, compared to analysts' expectations of $21.72 million. SOPHiA GENETICS had a negative return on equity of 132.47% and a negative net margin of 93.86%. On average, equities research analysts anticipate that SOPHiA GENETICS SA will post -0.77 EPS for the current year.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in SOPH. AXQ Capital LP acquired a new stake in shares of SOPHiA GENETICS in the second quarter valued at approximately $119,000. AWM Investment Company Inc. acquired a new stake in SOPHiA GENETICS during the 2nd quarter worth $9,809,000. Hennion & Walsh Asset Management Inc. purchased a new stake in shares of SOPHiA GENETICS in the second quarter valued at about $567,000. Royal Bank of Canada grew its holdings in shares of SOPHiA GENETICS by 3,130.2% during the first quarter. Royal Bank of Canada now owns 19,381 shares of the company's stock worth $96,000 after buying an additional 18,781 shares during the last quarter. Finally, Sei Investments Co. purchased a new position in shares of SOPHiA GENETICS during the first quarter worth about $1,772,000. Institutional investors and hedge funds own 31.59% of the company's stock.

Wall Street Analyst Weigh In

SOPH has been the topic of several research analyst reports. BTIG Research raised their target price on SOPHiA GENETICS from $8.00 to $9.00 and gave the stock a "buy" rating in a research report on Wednesday, August 5th. Zacks Research upgraded shares of SOPHiA GENETICS to a "hold" rating in a research note on Tuesday, July 21st. Weiss Ratings reissued a "sell (d-)" rating on shares of SOPHiA GENETICS in a report on Friday, July 17th. Finally, HC Wainwright boosted their price objective on shares of SOPHiA GENETICS from $12.00 to $14.00 and gave the stock a "buy" rating in a research report on Wednesday, August 5th. Three research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat, the stock currently has an average rating of "Hold" and a consensus target price of $10.00.

About SOPHiA GENETICS

SOPHiA GENETICS SA is a data-driven medicine company founded in 2011 and headquartered in La Tène, Switzerland. The firm develops and operates a cloud-native software platform designed to standardize and analyze complex genomic and radiomic data. Its core offering, the SOPHiA DDM™ platform, leverages artificial intelligence and machine learning algorithms to help healthcare institutions, laboratories and biopharmaceutical partners derive actionable insights from next-generation sequencing and medical imaging datasets.

The SOPHiA DDM™ platform supports a range of clinical applications, including oncology, hereditary diseases and rare genetic disorders.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source